This document has not been cited yet.

1. Aitken, M. ; Blansett, L. ; Mawrie, R. Developments in cancer treatments, market dynamics, patient access and value. 2015 IMS Institut for Health Care and Informatics:
   Paper not yet in RePEc: Add citation now
   

2. Appleby, J. ; Devlin, N. ; Parkin, D. ; Buxton, M. ; Chalkidou, K. Searching for cost effectiveness thresholds in the nhs. 2009 Health Policy. 91 239-245

3. Bach, P.B. Indication-specific pricing for cancer drugs. 2014 JAMA. 312 1629-1630
   Paper not yet in RePEc: Add citation now
   
4. Brekke, K.R. ; Dalen, D.M. ; Straume, O.R. Competing with precision: incentives for developing predictive biomarker tests. 2024 Scand J Econ. 126 60-97
   Paper not yet in RePEc: Add citation now
   
5. Chandra, A. ; Garthwaite, C. The economics of indication-based drug pricing. 2017 N Engl J Med. 377 103-106
   Paper not yet in RePEc: Add citation now
   
6. Claxton, K. OFT, VBP: Qed?. 2007 Health Econ. 16 545-558
   Paper not yet in RePEc: Add citation now
   
7. Claxton, K. ; Briggs, A. ; Buxton, M. ; Culyer, A. ; McCabe, C. ; Walke, S. Value based pricing for NHS drugs: an opportunity not to be missed?. 2008 BMJ. 336 252-254
   Paper not yet in RePEc: Add citation now
   

8. Claxton, K. ; Sculpher, M. ; Carroll, S. Value-based pricing for pharmaceuticals: Its role, specification and prospects in a newly devolved nhs. 2011 Centre for Health Economics, University of York:

9. Coyle, D. ; Buxton, M.J. ; O’Brien, B.J. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. 2003 Health Econ. 12 421-427
   Paper not yet in RePEc: Add citation now
   
10. Danzon, P. ; Towse, A. ; Mestre-Ferrandiz, J. Value-based differential pricing: Efficient prices for drugs in a global context. 2015 Health Econ. 24 294-301
    Paper not yet in RePEc: Add citation now
    
11. Eichler, H.-G. ; Abadie, E. ; Breckenridge, A. ; Flamion, B. ; Gustafsson, L.L. ; Leufkens, H. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. 2011 Nat Rev Drug Discov. 10 495-506
    Paper not yet in RePEc: Add citation now
    

12. Garattini, L. ; Padula, A. Competition in pharmaceuticals: more product- than price-oriented?. 2018 Eur J Health Econ. 19 1-4

13. Gibson, S. ; von Tigerstrom, B. Orphan drug incentives in the pharmacogenomic context: policy responses in the us and Canada. 2015 J Law Biosci. 2 263-291
    Paper not yet in RePEc: Add citation now
    

14. Gravelle, H.S. Ex post value reimbursement for pharmaceuticals. 1998 Med Decis Mak. 18 S27-S38

15. Haslam, A. ; Kim, M.S. ; Prasad, V. Overall survival for oncology drugs approved for genomic indications. 2022 Eur J Cancer. 160 175-179
    Paper not yet in RePEc: Add citation now
    
16. Hawkins, N. ; Scott, D.A. Reimbursement and value-based pricing: stratified cost-effectiveness analysis may not be the last word. 2011 Health Econ. 20 688-698
    Paper not yet in RePEc: Add citation now
    

17. Hlávka, J.P. ; Yu, J.C. ; Goldman, D.P. ; Lakdawalla, D.N. The economics of alternative payment models for pharmaceuticals. 2021 Eur J Health Econ. 22 559-569

18. Howard, D.H. ; Bach, P.B. ; Berndt, E.R. ; Conti, R.M. Pricing in the market for anticancer drugs. 2015 J Econ Perspect. 29 139-162

19. Jena, A.B. ; Philipson, T.J. Endogenous cost-effectiveness analysis and health care technology adoption. 2013 J Health Econ. 32 172-180

20. Kaltenboeck, A. ; Bach, P. Value-based pricing for drugs: Theme and variations. 2018 JAMA. 319 2165-2166
    Paper not yet in RePEc: Add citation now
    

21. Lakdawalla, D.N. Economics of the pharmaceutical industry. 2018 J Econ Lit. 56 397-449

22. Ledley, F.D. ; McCoy, S.S. ; Vaughan, G. ; Cleary, E.G. Profitability of large pharmaceutical companies compared with other large public companies. 2020 JAMA. 323 834-
    Paper not yet in RePEc: Add citation now
    
23. Levaggi, L. ; Levaggi, R. Pricing personalised drugs: Comparing indication value based prices with performance based schemes. 2024 B.E. J Econ Anal Policy. -
    Paper not yet in RePEc: Add citation now
    

24. Levaggi, L. ; Levaggi, R. Welfare properties of restrictions to health care based on cost effectiveness. 2011 Health Econ. 20 101-110

25. Levaggi, R. Pricing schemes for new drugs: A welfare analysis. 2014 Soc Sci Med. 102 69-73

26. Levaggi, R. ; Pertile, P. Value-based pricing alternatives for personalised drugs: Implications of asymmetric information and competition. 2020 Appl Health Econ Health Policy. 18 357-362

27. Levaggi, R. ; Pertile, P. Which valued-based price when patients are heterogeneous?. 2020 Health Econ. 29 923-935

28. Mailankody, S. ; Prasad, V. Five years of cancer drug approvals. 2015 JAMA Oncol. 1 539-
    Paper not yet in RePEc: Add citation now
    

29. Michaeli, D.T. ; Mills, M. ; Kanavos, P. Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland. 2022 Appl Health Econ Health Policy. 20 757-768

30. Mills, M.J. ; Michaeli, D. ; Miracolo, A. ; Kanavos, P. Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries. 2023 BMC Health Serv Res. 23 150-
    Paper not yet in RePEc: Add citation now
    

31. Pertile, P. ; Forster, M. ; Torre, D.L. Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies. 2014 J R Stat Soc Ser A. 177 419-438

32. Preckler, V. ; Espín, J. The role of indication-based pricing in future pricing and reimbursement policies: A systematic review. 2022 Value Health. 25 666-675
    Paper not yet in RePEc: Add citation now
    

33. Salas-Vega, S. ; Shearer, E. ; Mossialos, E. Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US. 2020 Soc Sci Med. 258 -

34. Schork, N. Personalized medicine: Time for one-person trials. 2015 Nature. 520 609-611

35. Sculpher, M. Subgroups and heterogeneity in cost-effectiveness analysis. 2008 PharmacoEconomics. 26 799-806
    Paper not yet in RePEc: Add citation now
    
36. Smith, R. Stratified, personalised, or precision medicine. 2012 BMJ Blogs. -
    Paper not yet in RePEc: Add citation now
    

37. Sussex, J. ; Towse, A. ; Devlin, N. Operationalizing value-based pricing of medicines. 2013 PharmacoEconomics. 31 1-10

38. Vokinger, K.N. ; Kesselheim, A.S. Value-based pricing of drugs with multiple indications or in combinations - lessons from Europe. 2021 Nat Rev Clin Oncol. 19 1-2
    Paper not yet in RePEc: Add citation now
    
39. Yu, N. ; Helms, Z. ; Bach, P.B. R & D costs for pharmaceutical companies do not explain elevated US drug prices. 2017 Health Affairs Blog. -
    Paper not yet in RePEc: Add citation now
    

1. Competition, value-based prices and incentives to research personalised drugs. (2024). LEVAGGI, ROSELLA.
   In: Socio-Economic Planning Sciences.
   RePEc:eee:soceps:v:93:y:2024:i:c:s0038012124000697.

   Full description at Econpapers || Download paper

2. The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS. (2022). Asaria, Miqdad ; Baal, Pieter ; Perry-Duxbury, Megan ; Lomas, James.
   In: PharmacoEconomics.
   RePEc:spr:pharme:v:40:y:2022:i:2:d:10.1007_s40273-021-01090-x.

   Full description at Econpapers || Download paper

3. Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy. (2022). Towse, Adrian ; Sampson, Christopher ; Devlin, Nancy ; Garcia-Lorenzo, Borja ; Zamora, Bernarda ; Leech, Ashley A ; Watson, Sam ; Cubi-Molla, Patricia ; Chalkidou, Kalipso ; Cairns, John ; Hughes, Dyfrig A.
   In: Applied Health Economics and Health Policy.
   RePEc:spr:aphecp:v:20:y:2022:i:5:d:10.1007_s40258-022-00730-3.

   Full description at Econpapers || Download paper

4. Strategies for Avoiding Neglect of Opportunity Costs by Decision-Makers. (2022). Karnon, Jonathan ; Afzali, Hossein ; Partington, Andrew.
   In: Applied Health Economics and Health Policy.
   RePEc:spr:aphecp:v:20:y:2022:i:1:d:10.1007_s40258-021-00681-1.

   Full description at Econpapers || Download paper

5. Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment. (2022). Faria, Rita ; Ochalek, Jessica ; Lomas, James.
   In: Applied Health Economics and Health Policy.
   RePEc:spr:aphecp:v:20:y:2022:i:1:d:10.1007_s40258-021-00679-9.

   Full description at Econpapers || Download paper

6. The relevance of including future healthcare costs in cost-effectiveness threshold calculations for the UK NHS. (2022). Asaria, Miqdad ; van Baal, Pieter ; Perry-Duxbury, Megan ; Lomas, James.
   In: LSE Research Online Documents on Economics.
   RePEc:ehl:lserod:112503.

   Full description at Econpapers || Download paper

7. The health cost of reducing hospital bed capacity. (2022). Henriksson, Martin ; Siverskog, Jonathan.
   In: Social Science & Medicine.
   RePEc:eee:socmed:v:313:y:2022:i:c:s0277953622007055.

   Full description at Econpapers || Download paper

8. NICE’s Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests. (2021). Paulden, Mike ; Omahony, James F ; McCabe, Chris.
   In: PharmacoEconomics.
   RePEc:spr:pharme:v:39:y:2021:i:2:d:10.1007_s40273-020-00990-8.

   Full description at Econpapers || Download paper

9. Mutually Exclusive Interventions in the Cost-Effectiveness Bookshelf. (2020). Henriksson, Martin ; Siverskog, Jonathan.
   In: Medical Decision Making.
   RePEc:sae:medema:v:40:y:2020:i:3:p:399-403.

   Full description at Econpapers || Download paper

10. Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL). (2018). Hampson, Grace ; Garau, Martina ; Devlin, Nancy ; Profico, Antonio ; Mazzanti, Nicola Amedeo.
    In: PharmacoEconomics - Open.
    RePEc:spr:pharmo:v:2:y:2018:i:2:d:10.1007_s41669-017-0048-x.

    Full description at Econpapers || Download paper

11. Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System. (2018). Cheng, Terence ; Edney, Laura Catherine ; Karnon, Jonathan ; Ali, Hossein Haji.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:36:y:2018:i:2:d:10.1007_s40273-017-0585-2.

    Full description at Econpapers || Download paper

12. Using CART to Identify Thresholds and Hierarchies in the Determinants of Funding Decisions. (2017). Mortimer, Duncan ; Dalziel, Kim ; Schilling, Chris.
    In: Medical Decision Making.
    RePEc:sae:medema:v:37:y:2017:i:2:p:173-182.

    Full description at Econpapers || Download paper

13. Rationing in health care provision: a welfare approach. (2017). LEVAGGI, ROSELLA.
    In: International Journal of Health Economics and Management.
    RePEc:kap:ijhcfe:v:17:y:2017:i:2:d:10.1007_s10754-016-9209-1.

    Full description at Econpapers || Download paper

14. Sustainable Financing of Innovative Therapies: A Review of Approaches. (2016). Hollis, Aidan.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:34:y:2016:i:10:d:10.1007_s40273-016-0416-x.

    Full description at Econpapers || Download paper

15. Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma. (2016). Polinder, Suzanne ; Bruno, Marco J ; Peppelenbosch, Maikel P ; Lordick, Florian ; Janmaat, Vincent T ; Lorenzen, Sylvie.
    In: PLOS ONE.
    RePEc:plo:pone00:0153943.

    Full description at Econpapers || Download paper

16. Welfare analysis of rationing in health care provision. (2016). LEVAGGI, ROSELLA.
    In: Working papers.
    RePEc:ipu:wpaper:39.

    Full description at Econpapers || Download paper

17. Supporting the development of an essential health package: principles and initial assessment for Malawi. (2016). Sculpher, Mark ; Revill, Paul ; Claxton, Karl ; Ochalek, Jessica ; Rollinger, Alexandra.
    In: Working Papers.
    RePEc:chy:respap:136cherp.

    Full description at Econpapers || Download paper

18. The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions. (2015). Rice, Nigel ; Parkin, David ; O'Neill, Phill ; Feng, Yan ; Devlin, Nancy ; Dakin, Helen.
    In: Health Economics.
    RePEc:wly:hlthec:v:24:y:2015:i:10:p:1256-1271.

    Full description at Econpapers || Download paper

19. Local health care expenditure plans and their opportunity costs. (2015). Karlsberg, Sarah ; Karlsberg Schaffer, Sarah ; Devlin, Nancy ; Sussex, Jon ; Walker, Andrew.
    In: Health Policy.
    RePEc:eee:hepoli:v:119:y:2015:i:9:p:1237-1244.

    Full description at Econpapers || Download paper

20. STAR€”People-Powered Prioritization. (2014). Airoldi, Mara ; Bevan, Gwyn ; Morton, Alec.
    In: Medical Decision Making.
    RePEc:sae:medema:v:34:y:2014:i:8:p:965-975.

    Full description at Econpapers || Download paper

21. Pricing schemes for new drugs: A welfare analysis. (2014). LEVAGGI, ROSELLA.
    In: Social Science & Medicine.
    RePEc:eee:socmed:v:102:y:2014:i:c:p:69-73.

    Full description at Econpapers || Download paper

22. Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall. (2013). van Exel, Job ; Brouwer, Werner ; Wetering, E. ; Stolk, E..
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:14:y:2013:i:1:p:107-115.

    Full description at Econpapers || Download paper

23. Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold. (2013). Towse, Adrian ; Karlsberg, Sarah ; Karlsberg Schaffer, Sarah ; Barnsley, P ; Sussex, J.
    In: Occasional Paper.
    RePEc:ohe:occpap:000106.

    Full description at Econpapers || Download paper

24. The influence of cost-effectiveness and other factors on NICE decisions. (2013). Rice, Nigel ; Parkin, David ; Devlin, Nancy ; Feng, Yan ; OaNeill, Phill ; Dakin, Helen.
    In: Working Papers.
    RePEc:chy:respap:93cherp.

    Full description at Econpapers || Download paper

25. Comparing costs and outcomes across programmes of health care. (2012). Rice, Nigel ; Martin, Stephen ; Smith, Peter C..
    In: Health Economics.
    RePEc:wly:hlthec:v:21:y:2012:i:3:p:316-337.

    Full description at Econpapers || Download paper

26. The Cost Effectiveness of Newer Epilepsy Treatments. (2012). Bolin, Kristian ; Forsgren, Lars .
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:30:y:2012:i:10:p:903-923.

    Full description at Econpapers || Download paper

27. The monetary value of a life year: evidence from a qualitative study of treatment costs. (2011). Richardson, Jeff ; Hurworth, Rosalind ; McKie, John ; Shrimpton, Bradley .
    In: Health Economics.
    RePEc:wly:hlthec:v:20:y:2011:i:8:p:945-957.

    Full description at Econpapers || Download paper

28. Welfare properties of restrictions to health care based on cost effectiveness. (2011). LEVAGGI, ROSELLA.
    In: Health Economics.
    RePEc:wly:hlthec:v:20:y:2011:i:1:p:101-110.

    Full description at Econpapers || Download paper

29. Shifting the risk in pricing and reimbursement schemes? A model of risk-sharing agreements for innovative drugs. (2011). LEVAGGI, ROSELLA ; Capri, Stefano.
    In: DEP - series of economic working papers.
    RePEc:gea:wpaper:2/2011.

    Full description at Econpapers || Download paper

30. Appropriate Perspectives for Health Care Decisions. (2010). Walker, Simon ; Sculpher, Mark ; Claxton, Karl ; Palmer, Steven.
    In: Working Papers.
    RePEc:chy:respap:54cherp.

    Full description at Econpapers || Download paper

31. Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?. (2009). Johannesson, Magnus ; Zethraeus, N ; Jonsson, L ; Kobelt, G.
    In: Briefing.
    RePEc:ohe:briefg:000228.

    Full description at Econpapers || Download paper

Report date: 2025-10-05 06:46:54 || Missing content? Let us know